Rein Therapeutics (NASDAQ:RNTX) Trading Down 1.8% – Time to Sell?

Posted by Brenda Bartman on Jul 12th, 2026

Rein Therapeutics Inc. (NASDAQ:RNTX – Get Free Report) dropped 1.8% on Friday . The stock traded as low as $0.9410 and last traded at $0.98. Approximately 148,430 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 579,701 shares. The stock had previously closed at $0.9978.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Rein Therapeutics in a research note on Friday, June 26th. HC Wainwright decreased their price objective on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Finally, Wall Street Zen upgraded Rein Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.00.

Check Out Our Latest Report on RNTX

Rein Therapeutics Stock Performance

The firm has a market capitalization of $83.83 million, a price-to-earnings ratio of -0.52 and a beta of 1.35. The company has a 50-day moving average of $1.02 and a 200-day moving average of $1.21.

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.30. As a group, analysts anticipate that Rein Therapeutics Inc. will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Rein Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Voss Capital LP grew its stake in shares of Rein Therapeutics by 59.2% during the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock worth $4,923,000 after acquiring an additional 1,577,437 shares in the last quarter. Cable Car Capital LP bought a new stake in shares of Rein Therapeutics in the second quarter worth $588,000. Vanguard Group Inc. lifted its position in shares of Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after purchasing an additional 284,300 shares in the last quarter. Geode Capital Management LLC acquired a new position in Rein Therapeutics during the second quarter worth $344,000. Finally, Texas Capital Bank Wealth Management Services Inc boosted its holdings in Rein Therapeutics by 901.6% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 262,125 shares of the company’s stock worth $304,000 after purchasing an additional 235,954 shares during the last quarter. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Rein Therapeutics

(Get Free Report)

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.